TargetMol

SV293

Product Code:
 
TAR-T28890
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28890-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28890-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28890-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SV293 is a selective antagonist of D2 dopamine receptor.
CAS:
873445-73-9
Formula:
C22H26N2O2S
Molecular Weight:
382.52
Purity:
0.98
SMILES:
COc1ccc2[nH]cc(CN3CCC(O)(CC3)c3ccc(SC)cc3)c2c1

References

1. Rangel-Barajas C, Malik M, Vangveravong S, Mach RH, Luedtke RR. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds. Neuropharmacology. 2014 Aug;83:18-27. doi: 10.1016/j.neuropharm.2014.03.003. Epub 2014 Mar 26. PubMed PMID: 24680675. 2. Huang R, Griffin SA, Taylor M, Vangveravong S, Mach RH, Dillon GH, Luedtke RR. The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition. Pharmacology. 2013;92(1-2):84-9. doi: 10.1159/000351971. Epub 2013 Aug 10. PubMed PMID: 23942137. 3. Luedtke RR, Mishra Y, Wang Q, Griffin SA, Bell-Horner C, Taylor M, Vangveravong S, Dillon GH, Huang RQ, Reichert DE, Mach RH. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. ACS Chem Neurosci. 2012 Dec 19;3(12):1050-62. doi: 10.1021/cn300142q. Epub 2012 Oct 12. PubMed PMID: 23259040; PubMed Central PMCID: PMC3526968. 4. Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH, Luedtke RR. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology. 2009 May-Jun;56(6-7):956-69. doi: 10.1016/j.neuropharm.2009.01.019. Epub 2009 Feb 5. PubMed PMID: 19371586; PubMed Central PMCID: PMC4106465.